Market Cap 4.51B
Revenue (ttm) 0.00
Net Income (ttm) -177.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 532,900
Avg Vol 1,404,256
Day's Range N/A - N/A
Shares Out 48.77M
Stochastic %K 81%
Beta 0.21
Analysts Strong Sell
Price Target $160.64

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology
Sector: Healthcare
Phone: (763) 392-0123
Address:
2800 Campus Drive, Suite 140, Minneapolis, United States
TheTarkioTrader
TheTarkioTrader Aug. 19 at 11:04 AM
$CELC remember stick with this loser
0 · Reply
DipinDipout
DipinDipout Aug. 19 at 10:42 AM
$CELC **worth exploring** = **worth blocking**
0 · Reply
DipinDipout
DipinDipout Aug. 19 at 10:40 AM
$CELC go away pumpers…this garbage about “interesting” opportunities is posted all over other boards, BLOCKED!
0 · Reply
MurrayKummer360
MurrayKummer360 Aug. 19 at 9:09 AM
$KODK $CELC $NTDOY $IPO Kodak remains execution-dependent around imaging and specialty businesses, Celcuity remains focused on precision oncology, Nintendo benefits from gaming hardware and software demand, and IPO remains highly speculative. I'm watching execution, clinical progress, game launches, and liquidity.
0 · Reply
CDSTrading
CDSTrading Aug. 19 at 8:58 AM
$KODK $CELC $NTDOY $IPO Kodak remains execution-dependent around imaging and specialty businesses, Celcuity remains focused on precision oncology, Nintendo benefits from gaming hardware and software demand, and IPO remains highly speculative. I'm watching execution, clinical progress, game launches, and liquidity.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 18 at 10:12 PM
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 18 at 8:47 PM
$CELC CELC Insider Update — August 18 Two key Celcuity insiders reported significant increases in their equity positions: CEO Brian F. Sullivan: acquired 80,000 shares at $0, bringing his direct ownership to approximately 1.45 million shares. CFO Vicky Hahne: acquired 16,000 shares at $0 through vesting and also received 10,000 performance stock units tied to CELC achieving specified stock-price thresholds. Neither transaction was an open-market cash purchase, so I wouldn’t call these traditional insider buys. But the important takeaway is that both the CEO and CFO increased their equity exposure to CELC, and the CFO’s performance awards are specifically tied to the stock reaching higher price levels. That’s certainly constructive insider alignment, especially with both top executives increasing their exposure at this point in the company’s development.
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 18 at 6:36 PM
$CELC new institutional holders * Jefferies: 89,234 shares * CI Private Wealth: 12,015 * Seven Fleet: 16,252 * Fulcrum Asset Management: 2,808
0 · Reply
Lussu1986
Lussu1986 Aug. 18 at 1:22 AM
$CELC Here is a great interview with CELC CEO Brian Sullivan. https://youtu.be/V5VR6TDaz0E
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 17 at 11:20 PM
$CELC FDA approval ✅ NCCN Category 1 inclusion ✅ $754M cash / runway beyond 2029 ✅ Late Q3 commercial launch approaching ✅ PIK3CAm sNDA planned Q3 2026 ✅ The story has officially shifted from “will it get approved?” to “how big can this launch and label expansion get?” At ~$92, Citizens and Guggenheim are sitting near 90% upside. September could get interesting very quickly. $CELC
0 · Reply
Latest News on CELC
Celcuity Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

Celcuity Earnings Call Transcript: Q2 2026


Celcuity Earnings release: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

Celcuity Earnings release: Q2 2026


Celcuity Quarterly report: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

Celcuity Quarterly report: Q2 2026


Celcuity Transcript: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 5 weeks ago

Celcuity Transcript: FDA announcement


Celcuity Press release: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 5 weeks ago

Celcuity Press release: FDA announcement


Celcuity Slides: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 5 weeks ago

Celcuity Slides: FDA announcement


Celcuity Slides: Corporate presentation

Jul 14, 2026, 4:00 PM EDT - 5 weeks ago

Celcuity Slides: Corporate presentation


US FDA approves Celcuity's breast cancer drug

Jul 14, 2026, 3:29 PM EDT - 5 weeks ago

US FDA approves Celcuity's breast cancer drug

CELC


Celcuity Slides: FY 2026

Jun 10, 2026, 8:00 AM EDT - 2 months ago

Celcuity Slides: FY 2026


Celcuity Transcript: Study result

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Celcuity Transcript: Study result


Celcuity Press release: Study result

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Celcuity Press release: Study result


Celcuity Slides: Study result

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Celcuity Slides: Study result


Celcuity To Participate in Upcoming Investor Conferences

May 28, 2026, 8:30 AM EDT - 2 months ago

Celcuity To Participate in Upcoming Investor Conferences

CELC


Celcuity Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Celcuity Earnings Call Transcript: Q1 2026


Celcuity Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Celcuity Earnings release: Q1 2026


Celcuity Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Celcuity Quarterly report: Q1 2026


Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Celcuity Proxy statement: Proxy filing


Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Celcuity Proxy statement: Proxy filing


Celcuity Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Celcuity Earnings Call Transcript: Q4 2025


Celcuity Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Celcuity Annual report: Q4 2025


Celcuity Earnings release: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Celcuity Earnings release: Q4 2025


Celcuity Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:20 PM EDT - 5 months ago

Celcuity Transcript: Leerink Global Healthcare Conference 2026


Celcuity Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 5 months ago

Celcuity Transcript: TD Cowen 46th Annual Health Care Conference


Celcuity Appoints Charles Romp to its Board of Directors

Feb 12, 2026, 4:05 PM EST - 6 months ago

Celcuity Appoints Charles Romp to its Board of Directors

CELC


Celcuity Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Celcuity Earnings Call Transcript: Q3 2025


Celcuity Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Celcuity Quarterly report: Q3 2025


Celcuity Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Celcuity Earnings release: Q3 2025


Celcuity Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:00 AM EST - 10 months ago

Celcuity Transcript: Stifel 2025 Healthcare Conference


Celcuity Transcript: Study Result

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Celcuity Transcript: Study Result


Celcuity Press release: Study Result

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Celcuity Press release: Study Result


Celcuity Slides: Study Result

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Celcuity Slides: Study Result


Celcuity Slides: Corporate Presentation

Oct 16, 2025, 7:00 AM EDT - 10 months ago

Celcuity Slides: Corporate Presentation


Celcuity Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings Call Transcript: Q2 2025


Celcuity Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings release: Q2 2025


Celcuity Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Quarterly report: Q2 2025


TheTarkioTrader
TheTarkioTrader Aug. 19 at 11:04 AM
$CELC remember stick with this loser
0 · Reply
DipinDipout
DipinDipout Aug. 19 at 10:42 AM
$CELC **worth exploring** = **worth blocking**
0 · Reply
DipinDipout
DipinDipout Aug. 19 at 10:40 AM
$CELC go away pumpers…this garbage about “interesting” opportunities is posted all over other boards, BLOCKED!
0 · Reply
MurrayKummer360
MurrayKummer360 Aug. 19 at 9:09 AM
$KODK $CELC $NTDOY $IPO Kodak remains execution-dependent around imaging and specialty businesses, Celcuity remains focused on precision oncology, Nintendo benefits from gaming hardware and software demand, and IPO remains highly speculative. I'm watching execution, clinical progress, game launches, and liquidity.
0 · Reply
CDSTrading
CDSTrading Aug. 19 at 8:58 AM
$KODK $CELC $NTDOY $IPO Kodak remains execution-dependent around imaging and specialty businesses, Celcuity remains focused on precision oncology, Nintendo benefits from gaming hardware and software demand, and IPO remains highly speculative. I'm watching execution, clinical progress, game launches, and liquidity.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 18 at 10:12 PM
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 18 at 8:47 PM
$CELC CELC Insider Update — August 18 Two key Celcuity insiders reported significant increases in their equity positions: CEO Brian F. Sullivan: acquired 80,000 shares at $0, bringing his direct ownership to approximately 1.45 million shares. CFO Vicky Hahne: acquired 16,000 shares at $0 through vesting and also received 10,000 performance stock units tied to CELC achieving specified stock-price thresholds. Neither transaction was an open-market cash purchase, so I wouldn’t call these traditional insider buys. But the important takeaway is that both the CEO and CFO increased their equity exposure to CELC, and the CFO’s performance awards are specifically tied to the stock reaching higher price levels. That’s certainly constructive insider alignment, especially with both top executives increasing their exposure at this point in the company’s development.
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 18 at 6:36 PM
$CELC new institutional holders * Jefferies: 89,234 shares * CI Private Wealth: 12,015 * Seven Fleet: 16,252 * Fulcrum Asset Management: 2,808
0 · Reply
Lussu1986
Lussu1986 Aug. 18 at 1:22 AM
$CELC Here is a great interview with CELC CEO Brian Sullivan. https://youtu.be/V5VR6TDaz0E
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 17 at 11:20 PM
$CELC FDA approval ✅ NCCN Category 1 inclusion ✅ $754M cash / runway beyond 2029 ✅ Late Q3 commercial launch approaching ✅ PIK3CAm sNDA planned Q3 2026 ✅ The story has officially shifted from “will it get approved?” to “how big can this launch and label expansion get?” At ~$92, Citizens and Guggenheim are sitting near 90% upside. September could get interesting very quickly. $CELC
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 17 at 10:16 PM
$CELC It is 129.76% definitely interesting, but I wouldn’t interpret it literally as institutions owning 130% of the company. Those institutional ownership databases can have overlapping/reported positions because of 13F/NPORT filings, securities lending, fund structures, etc. What is interesting is the direction: 63.5M institutional shares reported, up about 14M shares or 28% in the quarter, with 330 institutions increasing positions. So I’d call the 130% figure a reporting artifact, but the institutional accumulation itself is definitely worth watching.
0 · Reply
Quantumup
Quantumup Aug. 17 at 7:13 PM
Guggenheim⬆️ $CELC to $175, reiterated Buy and said -- CELC's update reiterated guidance for Revtorpyk commercial shipments to begin late in the third quarter, and management suggested this achievement could be press released. $NVS $RLAY RHHBY AZN Here's what else Guggenheim had to say: https://x.com/Quantumup1/status/2089430066442715375?s=20
0 · Reply
ripster47
ripster47 Aug. 17 at 2:35 PM
$CELC | Citizens Reiterates Celcuity at Market Outperform with $177.00 PT on Upcoming REVTORPYK Launch Citizens stays bullish as launch readiness and regulatory progress support continued upside. 🔹 Follow @tenet_research for more analyst insights on other tickers.
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 17 at 2:16 PM
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 17 at 1:26 PM
$CELC Citizens Reiterates Market Outperform on Celcuity, Maintains $177 Price Target
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 17 at 1:24 PM
$CELC Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175
0 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Aug. 17 at 12:58 PM
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 16 at 4:18 PM
$CELC The big August 14 CELC filings * Point72: 650,916 shares, +132.20% — roughly doubled its position. * Perceptive Advisors: 3,197,200 shares, +2.24% — essentially maintained/added slightly. * Sixth Street Partners: 320,893 shares — new reported position. * Blue Sparrow: 185,600 shares — new reported position. * Delaware Management: 204,516 shares — new reported position. * HighVista: 13,472 shares, +2.80%. * Susquehanna: 155,378 shares, +1,143.32% — that’s a huge increase in the reported common-stock position. * Freestone Grove: 67,907 shares, -3.73%. * Farallon: went to 0, exiting its reported position. * MAI Capital: went to 0. * Qube Research: went to 0. * Dark Forest: went to 0.
0 · Reply
heffer
heffer Aug. 15 at 8:37 PM
$CELC the Institutional ownership is back up to 110%.
1 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 15 at 5:52 PM
$CELC could it be that easy?
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 15 at 1:15 PM
$CELC And there’s another potential kicker: Celcuity is pursuing the PIK3CA-mutant indication after positive VIKTORIA-1 results, while VIKTORIA-2 is testing the drug in first-line disease. If those expand the label successfully, the addressable market could become considerably larger.
0 · Reply
Florestan
Florestan Aug. 15 at 8:24 AM
$CELC look up what "NCCN preferred Category 1" means. Revtorpyk is such drug. This thing is doing nearly 500M annual revenue next year and peak sales is estimated at 3-5B. You are buying below 1x peak and the take out price is usually 2-3x peak.
0 · Reply